| Homepage | Forward to a Friend | Make a Donation |
 |
| eLetter #740 | December 8, 2017 |
|
 |
Video: Coping with a Chronic Disease: Do You Have What it Takes?
Elaine Furst, R.N., recorded at the Scleroderma Foundation's 2017 Patient Education Conference, presents an evidenced-based, motivational talk to help people affected by scleroderma recognize the skills needed to take charge of their disease. Especially designed for people who are new to scleroderma, all are welcome.
watch video
|
 |
Open Enrollment Ends Dec. 15 for 2018 Health Insurance Under ACA
If you need health insurance for 2018 via the individual marketplace of the Affordable Care Act, the open enrollment period is now through December 15. Anyone who doesn't have coverage through a job, Medicare, Medicaid, the Children's Health Insurance Plan (CHIP), or other qualifying coverage is eligible to apply. Visit the HealthCare.gov website to learn more and sign up.
HealthCare.gov
|
 |
Scleroderma Research: Year in Review
Tracy M. Frech, M.D., of the Scleroderma Foundation's Medical and Scientific Advisory Board, highlights scleroderma research, medical advances, and clinical breakthroughs. Dr. Frech serves as Director of the Systemic Sclerosis Clinic at the University of Utah Hospital and as Director of Clinical Trials for the Division of Rheumatology. The one-hour webinar is a great educational resource for anyone interested in scleroderma.
watch video
|
 |
Grassroots Advocacy Training
Public policy advocacy on behalf of people affected by scleroderma at both the state and federal level makes a difference. The Scleroderma Foundation offers monthly grassroots advocacy training.
Webinar No. 3, December 11, 2017
Watch recordings of previous webinars:
|
 |
Anabasum shows acceptable safety, tolerability for diffuse system sclerosis
Watch video from the American College of Rheumatology Annual Meeting where Robert F. Spiera, M.D., of the Hospital for Special Surgery, speaks about the results of clinical trials for safety and efficacy of Anabasum in treating systemic sclerosis.
|
 |
Tocilizumab Benefits Persist in SSc
Clinically meaningful results, but not statistically significant
MedPageToday.com reports on the "faSScinate" study, a multinational randomized phase II trial of subcutaneous tocilizumab (known as Actemra). read more |
 |
Plan Ahead for 2018 for Stepping Out to Cure Scleroderma
Stepping out to Cure Scleroderma is the Scleroderma Foundation's signature fundraising event. Each year, this event helps our chapters and support groups raise important funds to find the cause and cure for scleroderma, and to provide the necessary support resources and free educational forums for patients and families.
Find Stepping Out walks for 2018
|
 |
2018 National Patient Education Conference
Sign up for e-Alerts to stay up to date on the 2018 National Patient Education Conference in Philadelphia, Pennsylvania, July 27-29.
sign up for e-alerts
|
 |
Support - Education - Research
Together, we make a difference for thousands of people affected by scleroderma. For the person who is newly diagnosed and looking for reliable answers, for the caregiver who is seeking advice on how to better help their loved one, for those living with scleroderma advocating for a better quality of life, and for all who share the common hope of finding a cure, we make a difference when we stand together.
The scleroderma community needs you now more than ever. Please make this a season of hope by taking action to eliminate scleroderma and making a year-end gift today to the Scleroderma Foundation.
|
|
|
| |
|
|
|
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
|
 |
|
